Wegovy

Wegovy is a prescription-only medicine containing the active ingredient semaglutide. It is licensed for chronic weight management in adults with obesity, or overweight adults with at least one weight-related health condition.

Semaglutide works by mimicking a natural hormone called GLP-1, which helps regulate appetite and food intake - helping you feel fuller for longer and reducing overall calorie intake.

Wegovy is administered as a once-weekly injection and is intended to be used alongside a reduced-calorie diet and increased physical activity, rather than as a standalone treatment.

Wegovy is licensed for adults with:

• A BMI of 30 kg/m² or above (obesity), or
• A BMI of 27 kg/m² or above (overweight), where at least one weight-related condition is also present (e.g. high blood pressure or type 2 diabetes)

A UK-registered clinician will confirm your eligibility before Wegovy is prescribed.

As a reputable online pharmacy in the UK, My London Pharmacy is proud to offer Wegovy as part of our weight management treatments. When you buy Wegovy from us, your order will be reviewed by a UK registered pharmacist, ensuring personalized care and safety. Our aim is to provide Wegovy at competitive prices, making it accessible to those seeking effective weight loss solutions in the UK.

We understand the importance of cost considerations when it comes to weight management medications. At My London Pharmacy, we strive to offer Wegovy at competitive prices, ensuring affordability without compromising on quality. The cost of Wegovy may vary based on the treatment duration and dosage required. We recommend consulting with our healthcare professionals to determine the most suitable Wegovy treatment plan for you.

Wegovy^® (semaglutide) injectionis indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) 

Limitations of Use

• Wegovy^® contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist
• The safety and effectiveness of Wegovy^® in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established
• Wegovy^® has not been studied in patients with a history of pancreatitis

Impact of Weight Loss Injections on Contraception

Important notice for patients using weight loss medications and taking the pill or HRT

Many patients are now using weight loss medications such as Semaglutide (Ozempic, Wegovy, Rybelsus) — either for diabetes management or privately for weight loss.

These medications work partly by slowing how your stomach empties, which can affect how well other medicines (like the contraceptive pill or HRT tablets) are absorbed by your body.

If you take the contraceptive pill:

This medicine may reduce how well the pill works. Semaglutide does not appear to reduce the effectiveness of the pill.

However, side effects such as vomiting or diarrhoea can still reduce how well the pill is absorbed.

Use extra protection (like condoms) if these occur and follow the missed pill rules as above.

If you’re taking Hormone Replacement Therapy (HRT):

This applies if your HRT includes progesterone tablets such as:

• Progesterone (Utrogestan)
• Norethisterone
• Medroxyprogesterone acetate

There is some concern that weight loss medications like Semaglutide may reduce how well these tablets are absorbed. This could cause irregular bleeding and may affect the protection of your womb lining, potentially increasing the risk of endometrial cancer.

Please contact your prescriber or pharmacy team to discuss your HRT or contraception options while using weight loss medication.

Cardiovascular Benefits

Wegovy has been shown to provide benefits beyond weight loss:

• In the SELECT trial (2023), Wegovy reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in adults with overweight or obesity and established heart disease.
• It can also improve blood pressure, cholesterol, and inflammatory markers, contributing to better overall heart health.

Average Weight Loss Results

Clinical studies show that:

• Participants using Wegovy 2.4 mg once weekly lost an average of 15-17% of their body weight over 68 weeks.
• Around one-third of users lost more than 20% of their starting weight when combined with a healthy diet and physical activity.
• Weight loss typically builds up gradually, with visible results after 8–12 weeks and maximum benefit over several months.

The MHRA approved a maximum dose of 7.2mg per week of semaglutide (Wegovy) on 6 January 2026, for adult patients with obesity only (BMI ≥30kg/m²). It is given as 3 injections of 2.4mg on the same day, at least 5cm apart, with the needle changed between each injection. Patients must have been on 2.4mg for a minimum of 4 weeks before stepping up. This higher dose does not apply to patients using Wegovy for heart risk reduction or those with a BMI under 30. Always follow your prescriber's instructions. For more information, visit the MHRA's official announcement, or read our full guide to the 7.2mg dose.

Clinical Evidence (STEP UP Trial, 72 weeks):

• Average body weight reduction of 18.7% vs 3.9% with placebo
• 89% of patients lost 5% or more of body weight vs 38% with placebo
• 31% of patients lost 25% or more of body weight vs 0% with placebo

Wegovy (Semaglutide) Multi-Dose Treatment Packs – Important Information

Wegovy can cause side effects, particularly when starting treatment or increasing the dose. Common side effects include nausea, vomiting, diarrhoea, constipation, abdominal pain, indigestion, reduced appetite, headache, and bloating.

Not all patients tolerate dose increases at the same rate. Some patients may need to remain on a lower dose for longer than planned, delay dose escalation, or discontinue treatment following clinical review.

If you are new to Wegovy or have not previously completed dose escalation successfully, please carefully consider whether purchasing a treatment pack containing multiple strengths (0.25 mg, 0.5 mg, and 1 mg) is appropriate for you.

As prescription medicines cannot be reused or resold once supplied, all dispensed medicines are non-returnable and non-refundable except where required by law. If your treatment needs to be adjusted due to side effects or tolerability issues, unused medication cannot be returned for a refund.

Novo Nordisk, the manufacturer of Wegovy, runs a free patient support programme offering injection guidance, dose reminders, and lifestyle resources. Visit wegovycare.co.uk to find out more.

This is an independent, third-party resource provided by Novo Nordisk and is separate from your treatment plan with My London Pharmacy.